Effect of aripiprazole on verbal memory and fluency in schizophrenic patients : results from the ESCAPE study.

Authors:
Chris Bervoets
Chris Bervoets
Collaborative Antwerp Psychiatric Research Institute (CAPRI)
Manuel Morrens
Manuel Morrens
Collaborative Antwerp Psychiatric Research Institute
Belgium
Kristof Vansteelandt
Kristof Vansteelandt
Katholieke Universiteit Leuven
Belgium
Veronique Halkin
Veronique Halkin
Psychiatric Hospital Onze Lieve Vrouw
Belgium
Eric Constant
Eric Constant
Université Catholique de Louvain
Belgium

CNS Drugs 2012 Nov;26(11):975-82

Psychiatric Hospital Onze Lieve Vrouw, Brugge, Belgium.

Background: Second-generation antipsychotics have gradually replaced first-generation antipsychotics as first-line treatment for patients with schizophrenia. Some positive effects on verbal cognition have been shown for the second-generation antipsychotics, but most studies are based on relatively small numbers of patients.

Objective: In the frame of the prospective, multi-centre, open-label study ESCAPE (A Prospective, Multicenter, Open-Label Study to Evaluate the Effectiveness and the Effect on Cognitive Function of a Treatment With Aripiprazole in a Broad Range of Schizophrenic Patients; clinicaltrials.gov identifier NCT00329810) evaluating the effectiveness and effect on cognitive functioning of aripiprazole in schizophrenic patients, we conducted a post hoc analysis to examine changes in verbal cognition and investigate the predictive value of a cognitive improvement on quality of life.

Study Design: This was a prospective, multi-centre, non-comparative, open-label study of aripiprazole in schizophrenic patients. At study enrolment, these patients were being treated with various first- or second-generation antipsychotics or were without previous antipsychotic treatment. On entering the study, all patients were treated with aripiprazole (Abilify(®); Otsuka, Tokyo, Japan) monotherapy; those patients who had received prior treatment with antipsychotics had their current drug(s) tapered off over a 2-week period. A post hoc analysis of the effect of aripiprazole on two verbal cognitive measures and their correlation with efficacy measures and quality of life was conducted.

Setting: Patients with schizophrenia were recruited in 56 psychiatric hospitals.

Patients: A total of 361 patients with schizophrenia, ranging from 18 to 65 years, entered the study.

Intervention: Patients were treated with aripiprazole monotherapy at a dosage of 10-30 mg/day. Those who were receiving first- or second-generation antipsychotics at enrolment were switched to aripiprazole monotherapy by tapering off their current drug(s) over a 2-week period.

Main Outcome Measure: Physician- and patient-rated parameters were measured to gain a complete view of the effectiveness of aripiprazole on the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) at baseline and at weeks 4, 8 and 12 and on the Clinical Global Impression-Severity of Illness (CGI-S) scale at baseline and at weeks 1, 2, 4, 8 and 12. A secondary endpoint of verbal cognitive function was measured by the California Verbal Learning Test (CVLT) and the Verbal Fluency (VF) test at baseline and at weeks 4 and 12. The hypothesis of an improvement in verbal cognition and its predictive value on the quality of life was formulated during data collection.

Results: 238 patients completed the study. A significant improvement in verbal cognition was observed from week 4 with the long term free recall (LTFR) in the CVLT over the scheduled visits in the trial (F(2,519) = 29.67, p < 0.0001). For the phonemic (letter) subtest of the VF test, patients scored significantly better at week 12 in comparison with baseline (F(2,519) = 3.57, p = 0.0289). There was no significant effect on the semantic (categories) subtest of the VF test (F(2,518) = 0.57, p = 0.5614). Improvement in CGI-S scores at a particular moment in time predicted improvement in LTFR scores at that same moment (F(1,519) = 38.38, p < 0.0001) and in the phonemic (F(1,519) = 42.77, p < 0.0001) and semantic (F(1,518) = 67.43, p < 0.0001) subtests of the VF test. Similarly, CGI-S score improvement globally predicted quality-of-life improvement over visits. The Q-LES-Q scales leisure (F(1,144) = 14.03, p < 0.0001) and social relations (F(1,469) = 5.28, p = 0.0220) also directly correlated with verbal cognition.

Conclusion: The findings suggest that switching to, or initiating aripiprazole in schizophrenic patients results in improvement in verbal cognitive functioning. The observed improvement on quality of life is explained by the effect of aripiprazole on the CGI-S score, though the leisure and social relations scales of the Q-LES-Q also independently correlated with verbal fluency. Randomized, controlled, clinical trials of this effect of aripiprazole for selected patients are needed.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40263-012-0003-4DOI Listing
November 2012
14 Reads

Publication Analysis

Top Keywords

second-generation antipsychotics
16
verbal cognition
16
schizophrenic patients
16
patients
12
open-label study
12
quality life
12
baseline weeks
12
patients treated
12
patients schizophrenia
12
aripiprazole
9
improvement verbal
8
cognitive function
8
verbal cognitive
8
post hoc
8
prospective multi-centre
8
aripiprazole monotherapy
8
aripiprazole schizophrenic
8
current drugs
8
hoc analysis
8
effectiveness cognitive
8

Similar Publications

A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study.

Eur Psychiatry 2007 Oct 7;22(7):433-43. Epub 2007 Jun 7.

Institute of Psychiatry, London, England.

Background: Naturalistic effectiveness trials of atypical antipsychotics are needed to provide broader information on efficacy, safety, and tolerability in patients with schizophrenia treated in a community practice setting.

Method: In this 26-week, open-label, multicentre study, patients with schizophrenia requiring a switch in antipsychotic medication because current medication was not well tolerated and/or clinical symptoms were not well controlled were randomized to receive aripiprazole or an atypical antipsychotic standard of care (SOC) treatment (i.e. Read More

View Article
October 2007

Predictors of early worsening after switch to aripiprazole: a randomized, controlled, open-label study.

Clin Drug Investig 2010 ;30(3):187-93

Department of Psychiatry, The Catholic University of Korea College of Medicine, Seoul, South Korea.

Background: Despite the increasing evidence relating to strategies for switching between different antipsychotics, little evidence is available about predictors of improvement or worsening while switching. In a previous study, we compared different options for switching to aripiprazole and found that patients with schizophrenia switched to aripiprazole with immediate discontinuation of the previous antipsychotic showed an increase in symptom severity after 1 week.

Objective: To identify predictors of worsening in the first 4 weeks after the switch to aripiprazole in partial non-responders to previous treatments. Read More

View Article
May 2010

Effectiveness of switching to aripiprazole from atypical antipsychotics in patients with schizophrenia.

Clin Neuropharmacol 2009 Sep-Oct;32(5):243-9

Department of Psychiatry, Chonnam National University Medical School, Gwangju, Republic of Korea.

Objective: To examine changes in cognitive function and clinical features after a switch from atypical antipsychotics to aripiprazole in patients with schizophrenia.

Method: Sixty-one patients with schizophrenia treated with atypical antipsychotics participated in this open-label, 26-week study. Antipsychotics were switched to aripiprazole, and neurocognitive functions were measured at 12 and 26 weeks using the computerized battery. Read More

View Article
June 2010

A prospective, multicentre, open-label study to evaluate the effectiveness of aripiprazole in the treatment of a broad range of patients with schizophrenia.

Eur Psychiatry 2012 Oct 14;27(7):506-12. Epub 2011 Sep 14.

Universitair Centrum Sint Jozef, Kortenberg, Belgium.

Purpose: The aim of this study is to evaluate the effectiveness of 12-week treatment with aripiprazole in a broad range of patients suffering from schizophrenia by using a variety of physicians, caregivers and patients scales.

Subjects And Methods: A total of 361 in- or outpatients who met Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria for schizophrenia received open-label aripiprazole (10-30 mg per day) in this 12-week, prospective, multicentre, uncontrolled study. The primary endpoint was the Clinical Global Impression-Improvement (CGI-I) scale which measured effectiveness of study medication, including efficacy, safety and tolerability. Read More

View Article
October 2012